Supercharged precision killers: Genetically engineered biomimetic drugs of screened metalloantibiotics against Acinetobacter baumanni

Xianyuan Wei,Bin Xue,Shuangchen Ruan,Jintong Guo,Yujing Huang,Xiaorui Geng,Dan Wang,Cangtao Zhou,Jun Zheng,Zhen Yuan

DOI: https://doi.org/10.1126/sciadv.adk6331

IF: 13.6

2024-03-23

Science Advances

Abstract:To eliminate multidrug-resistant bacteria of Acinetobacter baumannii , we screened 1100 Food and Drug Administration–approved small molecule drugs and accessed the broxyquinoline (Bq) efficacy in combination with various metal ions. Antibacterial tests demonstrated that the prepared Zn(Bq) 2 complex showed ultralow minimum inhibitory concentration of ~0.21 micrograms per milliliter with no resistance after 30 passages. We then constructed the nano zeolitic imidazolate framework-8 (ZIF-8) as a drug carrier of Zn(Bq) 2 and also incorporated the photosensitizer chlorin e6 (Ce6) to trace and boost the antibacterial effect. To further ensure the stable and targeted delivery, we genetically engineered outer membrane vesicles (OMVs) with the ability to selectively target A. baumannii . By coating the ZnBq/Ce6@ZIF-8 core with these OMV, the resulted drug (ZnBq/Ce6@ZIF-8@OMV) exhibited exceptional killing efficacy (>99.9999999%) of A. baumannii . In addition, in vitro and in vivo tests were also respectively carried out to inspect the remarkable efficacy of this previously unknown nanodrug in eradicating A. baumannii infections, including biofilms and meningitis.

multidisciplinary sciences

What problem does this paper attempt to address?

The primary aim of this paper is to address the issue of infections caused by multidrug-resistant bacterium *Acinetobacter baumannii*. *Acinetobacter baumannii* has become a significant pathogen in hospital-acquired infections due to its resistance to multiple existing antibiotics, posing a serious threat to public health. Specifically, the paper addresses the following key issues:

1. **Screening for effective antibacterial compounds**: By screening over 1,100 small molecule drugs approved by the U.S. Food and Drug Administration (FDA), researchers identified that the complex Zn(Bq)2, formed by bromquinoline (Bq) and zinc ions, has an ultra-low minimum inhibitory concentration (MIC), demonstrating strong antibacterial activity.

2. **Developing novel antibacterial drug carriers**: To improve the stability and targeted delivery capability of the drug, researchers utilized zeolitic imidazolate framework-8 (ZIF-8) as a drug carrier and incorporated the photosensitizer chlorin e6 (Ce6) to enhance antibacterial effects and facilitate tracking of the drug delivery process.

3. **Constructing targeted outer membrane vesicles (OMVs)**: By using genetic engineering techniques to modify *Escherichia coli*, the produced OMVs can specifically recognize and bind to *Acinetobacter baumannii*, ensuring effective drug delivery.

4. **Achieving synergistic antibacterial action**: By encapsulating the Zn(Bq)2/Ce6@ZIF-8 core within OMVs, forming ZnBq/Ce6@ZIF-8@OMVs nanodrug, the drug exhibits extremely high bactericidal efficiency (>99.9999999%), effectively eradicating *Acinetobacter baumannii* infections both in vitro and in vivo, including biofilms and meningitis.

In summary, this study successfully developed a highly effective antibacterial nanodrug targeting *Acinetobacter baumannii* by screening for potent antibacterial small molecules, designing novel drug carriers, and constructing targeted delivery systems. This provides a new therapeutic approach to combat multidrug-resistant bacteria.